MEIP - צמיחת הכנסות ב-12 חודשים נגררים MEI Pharma Corporation

MEI Pharma, Inc. (MEIP) develops targeted blood cancer therapies leveraging patent-protected molecules and a stable balance sheet. This GURU.Markets chart illustrates the year-over-year revenue change for the TTM, where the indicator level stands at 16.20. Business success is driven by the efficiency of joint research and cash reserves. The company's operations are strictly regulated by the FDA, including rules for the disposal of biomaterials.
MEI Pharma (MEIP) - פילוחי מדדים ודוחות פיננסיים

The year-over-year (TTM) commercial revenue growth trend reflects the commercial success of MEI Pharma, Inc. (MEIP) innovative oncology drugs, recording a current value of 16.20. This indicator measures the percentage change in sales over a rolling 12-month period, allowing investors to promptly assess cash flow resilience to macro shocks and accurately determine the capital entry point prior to the publication of quarterly reports.